Morningstar Launches New Digital Destination to Empower Asian Investors
SINGAPORE--(BUSINESS WIRE)-- Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today announced the launch of its new Asia digital investment research hub, designed to empower investors with localized investment research, data, and insights.
The new digital destination is free and offers region-specific investment and market content, data, and tools tailored to the needs of Asian investors. Part of a suite of 12 new digital experiences created for distinct markets around the world, today's launch reflects Morningstar's commitment to serving local investors, backed by the strength of the company's global independent research and long-term perspective. The new digital experiences replace legacy ones across markets.
'Our mission is to empower investor success, seeking to help investors reach their financial goals wherever they are in the world,' said Shihan Abeyguna, managing director of Southeast Asia for Morningstar. 'With this new experience, it's easier for Asian investors to access trusted research and tools designed to create transparency and support confident decision-making.'
Key features of the new platform include:
Localized Investment News and Analysis: Stay informed with region-specific updates on markets, stocks, funds, and economic trends.
Interactive Investment Screeners: Easily find funds and stocks that align with your goals using advanced filters including size, risk, ratings, and performance.
Personalized Watchlists: Organize investments by strategy, region, or goal with dynamic, unlimited watchlists.
Enhanced Morningstar Research Reports: Discover tailored fund reports designed for local regulatory frameworks and market conditions, with key metrics like ratings, risk, and performance front and center.
Free Membership: Unlock premium access to Morningstar's tools, insights, and member-only newsletters, all for free.
For more information, visit https://global.morningstar.com/en-ea?IDmarche=tw.
About Morningstar, Inc.
Morningstar, Inc. is a leading provider of independent investment insights in North America, Europe, Australia, and Asia. The Company offers an extensive line of products and services for individual investors, financial advisors, asset managers and owners, retirement plan providers and sponsors, institutional investors in the debt and private capital markets, and alliances and redistributors. Morningstar provides data and research insights on a wide range of investment offerings, including managed investment products, publicly listed companies, private capital markets, debt securities, and real-time global market data. Morningstar also offers investment management services through its investment advisory subsidiaries, with approximately $341 billion in AUMA as of March 31, 2025. The Company operates through wholly-owned subsidiaries in 32 countries. For more information, visit www.morningstar.com/company. Follow Morningstar on X @MorningstarInc.
©2025 Morningstar, Inc. All rights reserved.
MORN-P
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for accelerated approval of TXM for bird flu Phase 2 study protocol submitted to HREC to evaluate ratutrelvir in newly diagnosed COVID patients, with extensions to measure disease rebound and development of Long COVID NEWTOWN, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ('Traws Pharma', 'Traws' or 'the Company'), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced multiple regulatory submissions related to its antiviral pipeline. Tivoxavir marboxil A proposed Phase 2 dose-ranging, non-inferiority study will evaluate the effects of tivoxavir marboxil (TXM), a potential best in class CAP-dependent endonuclease inhibitor, compared to XOFLUZA®, in patients infected with seasonal influenza. A separate single arm will evaluate the effects of TXM in patients infected with H5N1 bird flu. The proposed study has been submitted for Human Research Ethics Committee (HREC) review and is expected to enroll subjects in Australia and selected countries in Southeast Asia (SE Asia) with high rates of human bird flu infections. 'This combined study, evaluating the effects of TXM in seasonal and bird flu patients, could support the broad use of TXM against multiple influenza strains,' commented Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention (CDC). 'The high rates of animal-to-human transmission of bird flu in SE Asia should allow us to evaluate the efficacy of TXM in this important clinical setting, adding to our robust pre-clinical efficacy results of TXM against bird flu.' Also, as a follow up to recent Pre-IND FDA interactions on TXM, Traws submitted briefing materials for a Type D meeting to enable further FDA dialog on a potential path to accelerated approval for bird flu. 'We are continuing to discuss with the FDA the applicability of the Animal Rule and other routes that could support an accelerated approval of TXM for bird flu,' commented C. David Pauza, PhD, Chief Science Officer for Traws Pharma. 'We look forward to continuing positive interactions with the Agency.' Ratutrelvir A proposed Phase 2 non-inferiority study will evaluate the effects of ratutrelvir, a potential best in class protease inhibitor that does not require ritonavir co-administration, compared to PAXLOVID®, in newly diagnosed COVID patients. The proposed study that has been submitted for HREC review is intended to enroll patients on a 10-day treatment regimen for ratutrelvir compared to the approved 5-day regimen for PAXLOVID®. In addition to efficacy and safety endpoints, the proposed study will also evaluate the rates of disease rebound as well as the incidence of Long COVID. A separate single arm will evaluate the safety and efficacy of ratutrelvir in newly diagnosed COVID patients who are ineligible for treatment with PAXLOVID®. 'A significant population of patients who are at risk for poor outcomes from COVID are ineligible for PAXLOVID®. In addition, rebound infections and prevention of the development of Long COVID are unaddressed by existing therapies. We believe ratutrelvir has the potential to overcome these issues,' commented Dr. Redfield. 'Our proposed Phase 2 study is expected to highlight the differentiating attributes of ratutrelvir compared to existing approved therapies.' 'Today's announcements demonstrate our commitment to rapidly advance our antiviral portfolio,' commented Iain D. Dukes, MA, DPhil, Interim Chief Executive Officer for Traws Pharma. 'We look forward to delivering these potentially vital medicines to patients.' About Tivoxavir Marboxil Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza. It has potent in vitro activity against a range of influenza strains in preclinical studies, including a human isolate of the highly pathogenic avian flu H5N1 (bird flu). Consistent, positive preclinical data from three animal species indicate that a single dose of TXM demonstrated a therapeutic effect against H5N1 bird flu. Seasonal influenza represents an estimated multi-billion dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders1,2, with upside potential from potential pandemic flu outbreaks including H5N1 bird flu. We believe that these data support further development of TXM as a treatment for bird flu. About Ratutrelvir Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to be a broadly acting treatment for COVID-19 that is used without ritonavir. It has demonstrated in vitro activity against a range of COVID-19 strains. Preclinical and Phase 1 studies show that ratutrelvir does not require co-administration with a metabolic inhibitor, such as ritonavir, which could avoid ritonavir-associated drug-drug interactions3, and potentially enable wider patient use. Phase 1 data also show that ratutrelvir's pharmacokinetic (PK) profile demonstrated maintenance of target blood plasma levels approximately 13 times above the EC50 using the target Phase 2 dosing regimen of 600 mg/day for ten days, which may also reduce the likelihood of clinical rebound and, consequently, reduce the risk for Long COVID4. Industry data indicate that COVID treatment represents a potential multi-billion dollar market opportunity5,6. Source information: Per link TRAW data on file Carly Herbert et al. (2025) Clinical Infectious Diseases. 10K report 2024, Feb 27, 2025 Merck & Co 10K, Feb 25, 2025 Third-party products mentioned herein are the trademarks of their respective owners. About Traws Pharma, Inc. Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease). Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws' website at For more information, please visit and follow us on LinkedIn. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, benefits and the regulatory plans for tivoxavir marboxil. The Company has attempted to identify forward-looking statements by terminology including 'believes', 'estimates', 'anticipates', 'expects', 'plans', 'intends', 'may', 'could', 'might', 'will', 'should', 'preliminary', 'encouraging', 'approximately' or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including our ability to proceed with our proposed clinical trials and to enroll sufficient subjects in such studies and trials, the success and timing of Traws' clinical trials, our ability to take advantage of expedited regulatory pathways for tivoxavir marboxil, our ability to obtain regulatory approval of tivoxavir marboxil and ratutrelvir, the expectations of our interactions with regulatory authorities, including the FDA, the Human Research Ethics Committee (HREC) and other international regulatory agencies, market conditions, regulatory requirements, changes in government regulation, the extent of the spread and threat of bird flu, seasonal influenza and COVID, and those discussed under the heading 'Risk Factors' in Traws' filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law. Traws Pharma Contact: Nora BrennanTraws Pharma, Investor Contact:John Fraunces LifeSci Advisors, LLC917-355-2395jfraunces@ in to access your portfolio
Yahoo
33 minutes ago
- Yahoo
Johnson Outdoors (NASDAQ:JOUT) Has Announced A Dividend Of $0.33
Johnson Outdoors Inc.'s (NASDAQ:JOUT) investors are due to receive a payment of $0.33 per share on 24th of July. The dividend yield will be 4.5% based on this payment which is still above the industry average. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. If the payments aren't sustainable, a high yield for a few years won't matter that much. Even though Johnson Outdoors isn't generating a profit, it is generating healthy free cash flows that easily cover the dividend. In general, cash flows are more important than the more traditional measures of profit so we feel pretty comfortable with the dividend at this level. The next year is set to see EPS grow by 157.8%. If the dividend continues along recent trends, we estimate the payout ratio will be 59%, which is in the range that makes us comfortable with the sustainability of the dividend. See our latest analysis for Johnson Outdoors Even over a long history of paying dividends, the company's distributions have been remarkably stable. Since 2015, the annual payment back then was $0.30, compared to the most recent full-year payment of $1.32. This implies that the company grew its distributions at a yearly rate of about 16% over that duration. We can see that payments have shown some very nice upward momentum without faltering, which provides some reassurance that future payments will also be reliable. Investors who have held shares in the company for the past few years will be happy with the dividend income they have received. However, things aren't all that rosy. Johnson Outdoors' earnings per share has shrunk at 46% a year over the past five years. Such rapid declines definitely have the potential to constrain dividend payments if the trend continues into the future. Over the next year, however, earnings are actually predicted to rise, but we would still be cautious until a track record of earnings growth can be built. Overall, we don't think this company makes a great dividend stock, even though the dividend wasn't cut this year. The company has been bring in plenty of cash to cover the dividend, but we don't necessarily think that makes it a great dividend stock. We would probably look elsewhere for an income investment. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Taking the debate a bit further, we've identified 1 warning sign for Johnson Outdoors that investors need to be conscious of moving forward. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Wire
34 minutes ago
- Business Wire
SINOVAC Board of Directors Urges Shareholders to Vote the WHITE Proxy Card 'AGAINST' the Misguided Proposals to Remove SINOVAC's Current Board
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ('SINOVAC' or the 'Company'), a leading provider of biopharmaceutical products in China, today sent a letter to shareholders ahead of the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). The full text of the letter follows: Dear SINOVAC Shareholder, It is time to act. Your vote at the upcoming Special Meeting of Shareholders will shape SINOVAC's future. SAIF has called this Special Meeting to reconstitute a remnant of the Former Board that the UK Privy Council deemed to be 'Imposters' in its final, non-appealable January 2025 ruling. Proposing this slate (the 'Reconstituted Imposter Former Board Slate') is the latest scheme by Advantech/Prime Success ('Advantech/Prime'), Vivo Capital (together, the 'Dissenting Investor Group'), and other members of the Former Management Buyout Consortium to seize control of SINOVAC at the expense of common shareholders. While your current SINOVAC Board has been delivering on its promises to restore fairness and deliver value to all SINOVAC shareholders, the Dissenting Investor Group has been continuing its attempt to derail our progress through misleading rhetoric, baseless claims and frivolous legal actions. Their self-serving strategies pose a direct threat to the value of your investment and the future of SINOVAC. The facts speak for themselves: COMMITMENT TO DECLARING DIVIDENDS Since it was installed by the Privy Council ruling, and in accordance with Antiguan law, in just four months, the current SINOVAC Board has: Declared a US$55.00 per common share special cash dividend due to be paid on July 7, 2025. Announced plans for an additional US$11.00 per common share cash dividend, contingent on the cancellation of the unauthorized PIPE shares acquired by Advantech/Prime and Vivo Capital. Decided to declare a second special cash dividend of US$19.00 per common share, with the potential of an additional US$3.73 per common share if the PIPE shares are cancelled. Adopted a policy to issue regular dividends out of surplus cash, with potential future distributions of US$20.00 - US$50.00 per common share. IN CONTRAST, the Imposter Former Board failed to declare any dividends to common shareholders during the seven years it presided over SINOVAC, while draining cash from subsidiaries for itself to the exclusion of common shareholders. Today, the Imposter Former Board blames litigation during 2018-2024 as the reason it couldn't pay dividends, but ironically, the litigation it tried to use as an excuse did not prevent the Imposter Former Board's cronies from pocketing more than US$2 billion in dividends from our operating subsidiary. In a statement from the Company's 2023 20-F filed in April 2024, the Board stated it did not 'have any present plan to pay any cash dividends on Sinovac Antigua's shares in the foreseeable future.' The Imposter Former Board did not say the non-dividend policy was because of litigation. However, the onslaught of baseless, multi-jurisdictional lawfare by the same bad actors did not prevent the current SINOVAC Board from declaring the US$55.00 per common share cash dividend. Their lawsuits, intended to interfere with the dividend payout to all valid shareholders, have been defeated in New York and Hong Kong. The Reconstituted Imposter Former Board Slate, while paying lip service to endorsing our US$55.00 per common share cash dividend, haven't yet supported the additional dividends we've declared or our new dividend policy. Their sudden interest in dividends is nothing more than a hollow promise. We believe they would seek to privatize the Company again at below market prices and deprive shareholders of their rightful cash distributions. Shareholders should be asking the Reconstituted Imposter Former Board Slate this question: will you publicly support the current SINOVAC Board's plans for additional cash dividends and the dividend policy it recently adopted? RESUMPTION OF GOOD RELATIONS WITH NASDAQ AND REGULATORS The current SINOVAC Board has done significant work to unwind the seven years of compliance shortcomings that occurred under the Imposter Former Board, which directly led to the NASDAQ trading halt. This work includes: Engaging senior NASDAQ officials to regain compliance, resume trading and support the US$55.00 per share special cash dividend. Launching a formal exploration of a future listing on the Stock Exchange of Hong Kong to promote liquidity, mitigate geopolitical risk and maximize shareholder value. Tasking its Audit Committee with conducting a process to evaluate and select a new independent registered public accounting firm and end the revolving door of auditing firms under the Imposter Former Board. IN CONTRAST, the Reconstituted Imposter Former Board Slate is responsible for the very issues they now claim they'll resolve. Their unlawful actions triggered the 2019 NASDAQ trading halt and forced the resignation of Grant Thornton, SINOVAC's former auditor, due to sham transactions. PROTECTING VALID SINOVAC SHAREHOLDERS AND PAYING DIVIDENDS IN THE FACE OF CONTINUOUS LAWFARE WAGED BY ADVANTECH/PRIME AND VIVO CAPITAL The current SINOVAC Board is committed to fighting the self-serving, continuous and wasteful lawfare from the Dissenting Investor Group, which includes filing suits in New York and Hong Kong, and seeking injunctions designed to interfere with the payment of the US$55.00 special cash dividend to all common shareholders. In response to this self-serving lawfare strategy, the current SINOVAC Board has: Vigorously defended our position and prevailed against Advantech/Prime in New York and Hong Kong. Committed to fighting to protect valid shareholders and redistribute funds that were improperly allocated to the invalid PIPE shareholders. IN CONTRAST, the Dissenting Investor Group continues to talk out of both sides of their mouth – pretending they are in favor of dividend payments while filing intentionally vague lawsuits intended to deprive common shareholders of rightful dividend payments. The Reconstituted Imposter Former Board Slate would allow these actions to continue unchecked. In addition to dividends, the current SINOVAC Board is taking the necessary steps to correct the injustices of the past, position the Company for a brighter future and enhance governance by: Accelerating the resumption of trading on NASDAQ and exploring future listings on other exchanges. Planning an annual meeting of shareholders in the second quarter of 2026 to nominate a full slate of highly-qualified and independent directors. Executing a global growth strategy to expand SINOVAC's business in China and globally, leveraging our position as a leading provider of vaccine products. IN CONTRAST, during the seven years it presided over the Company, the Imposter Former Board demonstrated a pattern of self-dealing that allowed Advantech/Prime, Vivo Capital and their cronies to loot billions of dollars from SINOVAC while common SINOVAC shareholders received nothing. During that time, the Imposter Former Board approved an invalid PIPE transaction, which is in the process of being unwound, gifted Advantech/Prime and Vivo Capital shares of SINOVAC's operating subsidiary, granted shares to select minority shareholders, doled out excessive bonuses to the SINOVAC management team, and enabled non-arms length investments by SINOVAC of nearly US$100 million in Vivo Capital Funds. Shareholders should ask themselves: do you think the Imposter Former Board Slate would really have all SINOVAC shareholders' best interests in mind? We doubt it. YOUR VOTE IS IMPORTANT The Special Meeting of Shareholders (the 'Special Meeting') will be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). Your vote determines SINOVAC's future, receipt of your dividend payments and the long-term value of your investment. The facts are clear, and so is the choice. We urge you to vote on the WHITE proxy card: ' AGAINST ' Proposal 1 to remove the current SINOVAC Board. ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! THANK YOU We thank you for your continued confidence and support as we work to protect your investment and the future of SINOVAC. If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ For more information, visit Sincerely, The SINOVAC Board of Directors About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
